Agenus Inc. · NASDAQ:AGEN

Agenus — Jefferies 2016 Healthcare Conference

29 slides from Agenus's conference presentation, June 2016

  1. Slide 1: Integrated Solutions in Immuno-Oncology

    Slide 1: Integrated Solutions in Immuno-Oncology

    Integrated Solutions in Immuno-Oncology Jefferies 2016 Healthcare Conference June 2016

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements. These forward- looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of our Quarterly Report on form 10-Q filed with the Securities and Exchange Commi

  3. Slide 3: Optimizing Immuno-Oncology Treatments

    Slide 3: Optimizing Immuno-Oncology Treatments

    Optimizing Immuno-Oncology Treatments - Portfolio of synergistic Immuno-Oncology interventions • Antibody programs: GITR*, OX40*, TIM-3*, LAG-3*, CTLA-4**, PD-1** and CEACAM1, and multiple undisclosed targets and Immuno-Modulator (IM) programs • Both personalized and off-the-shelf vaccines: Prophage

  4. Slide 4: 2014-2016: Multiple Transformative Events

    Slide 4: 2014-2016: Multiple Transformative Events

    2014-2016: Multiple Transformative Events $74.6M** Equity IONTAS & Capital Raise Selexis Initiation of 4-AB Incyte Alliance Transactions CTLA-4 Phase 1 $60.0M upfront* May 2015 Acquisition Nov 2015 Apr 2016 Feb 2014 Feb 2015 Merck Acquired In-licensed PhosImmune & Expected Alliance Yeast Display CEA

  5. Slide 5: Challenges and Opportunities in Immuno-oncology

    Slide 5: Challenges and Opportunities in Immuno-oncology

    Challenges and Opportunities in Immuno-oncology Multiple points of intervention for combination therapies Anti-OX40* Anti-GITR* The AGENUS OPPORTUNITY: 1 NME^ comprehensive I/O combinations ü Tailored mAb combinations ü Off-the-shelf or Personalized Cancer Anti-TIM-3* Vaccines Anti-LAG-3* ü Vaccine

  6. Slide 6: Proprietary / Partnered Antibodies, Vaccines & Adjuvants

    Slide 6: Proprietary / Partnered Antibodies, Vaccines & Adjuvants

    Proprietary / Partnered Antibodies, Vaccines & Adjuvants 6

  7. Slide 7: Lead Programs: Vaccines & Immunomodulatory Antibodies

    Slide 7: Lead Programs: Vaccines & Immunomodulatory Antibodies

    Lead Programs: Vaccines & Immunomodulatory Antibodies - CTLA-4 Antagonist: Clinically and commercially validated component of core I/O regimens • Commenced Phase 1 trial in April 2016 • Potential synergies with our vaccines - GITR Agonist: Relieves T reg-mediated immunosuppression in tumors • IND cl

  8. Slide 8: 2016: Anticipated Milestones

    Slide 8: 2016: Anticipated Milestones

    2016: Anticipated Milestones Initiate clinical trial for AutoSynVax™ Initiate GITR* Initiate Prophage™ within the next 12 ndGBM Initiate Phase 1 months randomized CPM+Vaccine studies combo trial H1 H1 2016 H2 Initiate additional CPM Phase 1 trial(s) GSK filing for regulatory Form additional approval

  9. Slide 9: Financial Overview

    Slide 9: Financial Overview

    Financial Overview - Funds raised in 2015: • Incyte partnership $60.0 million^ • Equity offering $74.6 million* • Royalty monetization $100.0 million** - Cash balance (as of 3/31/16): ~$148 million - Shares outstanding: ~86.9 million / Fully diluted ~ 103.0 million *** - Headquarters - Lexington, Ma

  10. Slide 10: Strategic Roadmap

    Slide 10: Strategic Roadmap

    Strategic Roadmap Projection 5 Years Out • Company with steady revenue from: − Prophage™, CTLA-4 and GITR − Possibly OX40 & ASV™/PSV™ How To Get There • Leading innovator in I/O R&D • Prioritize advancing programs to deliver revenues in 5 years • Produce data to support strategic alliances & monetiz

  11. Slide 11: Agenus Antibody Portfolio: ImmunoModulators

    Slide 11: Agenus Antibody Portfolio: ImmunoModulators

    Agenus Antibody Portfolio: ImmunoModulators (IMs) (CheckPoint Inhibitors and Checkpoint Modulators)

  12. Slide 12: Optimized Agenus Monoclonal Antibody (mAb) Platform

    Slide 12: Optimized Agenus Monoclonal Antibody (mAb) Platform

    Optimized Agenus Monoclonal Antibody (mAb) Platform Lead Lead IND Early Registrational Drug Profiling Generation Optimization Enabling Development Development Retrocyte Display™ HT-CHO Rationally-Enabled Optimization SECANT® Phage Display Cell Line Dev. GMP Production Yeast Display agenus West ( ) C

  13. Slide 13: AGEN Immunomodulatory Antibody Portfolio

    Slide 13: AGEN Immunomodulatory Antibody Portfolio

    AGEN Immunomodulatory Antibody Portfolio – 7 Disclosed CPM programs • 4 partnered with INCY • 3 Agenus retained*** – Multiple undisclosed immunomodulator programs • 1 partnered with MRK • 3 partnered with INCY • Multiple Agenus retained Targeting T-cells, other key immune cells, and TME components *

  14. Slide 14: Anti-CTLA-4 Antibodies Deplete Intra-tumoral Regulatory T Cells

    Slide 14: Anti-CTLA-4 Antibodies Deplete Intra-tumoral Regulatory T Cells

    Anti-CTLA-4 Antibodies Deplete Intra-tumoral Regulatory T Cells NK CELL Antibody-Dependent FcRs NK cell Cellular Cytotoxicity CTLA-4 Antibody Regulatory T cell (ADCC) - FcgRIIIA Regulatory TREG T cell depletion ADCC TREG Antibody-Dependent Cellular Phagocytosis CTLA-4 Antibody (ADCP) - FcgRIIA FcRs

  15. Slide 15: Agenus anti-CTLA-4 antagonists enhance primate vaccine responses

    Slide 15: Agenus anti-CTLA-4 antagonists enhance primate vaccine responses

    Agenus anti-CTLA-4 antagonists enhance primate vaccine responses Hepatitis B vaccine + anti-CTLA-4 antibody Antibody Vaccine Candidate A( Ig(IgG1) AG EN1884 G 1) Candidate BG(IgG2) A G E N 2 0 4 1 ( Ig 2) 2000000 2000000 Candidate A G E N 1 8 8 4A (N (N=6) Candidate A G E N 2 0 4 1B (N (N=6) =6) A n

  16. Slide 16: HSP-Based Vaccines & CPMs Synergize Pre-clinically

    Slide 16: HSP-Based Vaccines & CPMs Synergize Pre-clinically

    HSP-Based Vaccines & CPMs Synergize Pre-clinically HSPPC-96 + Anti-CTLA-4 Antibody: Immuno-education+immuno-modulation Murine breast cancer tumor model Antibody Vaccine Example: Prophage™ Series Tumor Size 87% CR Agenus data (unpublished) 16

  17. Slide 17: AGEN1884 Phase 1 Trial

    Slide 17: AGEN1884 Phase 1 Trial

    AGEN1884* Phase 1 Trial AGEN1884: An anti-CTLA-4 antagonist antibody Design • Open-label, multicenter study • Approx. 48 patients with advanced or refractory cancer Primary • Trial will evaluate safety of AGEN1884 and determine the Outcome estimated maximum tolerated dose Measures Status/Sites • Rec

  18. Slide 18: Anti-GITR Agonist Antibody (IND cleared Jan 2016)

    Slide 18: Anti-GITR Agonist Antibody (IND cleared Jan 2016)

    Anti-GITR Agonist Antibody (IND cleared Jan 2016)* Goal: Differentiated Mechanism of Action for Best-in-class Potential Example: Enhanced poly-functional T cell response by GITR agonist Isotype Donor ID#XXXX Anti-GITR control CD4+ 3% 3% 0% 1% T cells 12% 2% 10% 11% 3% 3% CD8+ T cells IFN γ 12% 5% TN

  19. Slide 19: Co-engagement of FcγRs Depletes Intra-tumoral Regulatory T Cells

    Slide 19: Co-engagement of FcγRs Depletes Intra-tumoral Regulatory T Cells

    Co-engagement of FcγRs Depletes Intra-tumoral Regulatory T Cells (Examples: GITR & OX40) Colon26 model Kinetics of Tregs depletion (within the tumor) 7.0 Density of FoxP3+ CD4+ Tumor Control 6.0 DTA-1 mIgG2a 5.0 DTA-1 N297A T cells 4.0 3.0 Lymph node 2.0 28-fold 1.0 0.0 0 1 2 3 4 5 6 Days post-treat

  20. Slide 20: Agenus Vaccine Programs

    Slide 20: Agenus Vaccine Programs

    Agenus Vaccine Programs: Innovative, individualized cancer vaccines Prophage™ AutoSynVax™ PhosphoSynVax™

  21. Slide 21: Heat-shock Protein-neo-epitope Complexes Confer Immunity

    Slide 21: Heat-shock Protein-neo-epitope Complexes Confer Immunity

    Heat-shock Protein-neo-epitope Complexes Confer Immunity HSP-containing fractions Protein Fractions tested confer anti-cancer immunity Tumor cells fractions from in vivo in tumors tumor rejection assays hsp70 hsp90 hsp110 gp96 grp170 CRT Cellular Peptides Chaperoning by HSPs • Abundant class of intr

  22. Slide 22: Prophage in ndGBM: Single Arm, Open Label Phase 2 Results

    Slide 22: Prophage in ndGBM: Single Arm, Open Label Phase 2 Results

    ProphageTM in ndGBM: Single Arm, Open Label Phase 2 Results Stratified by Initial PD-L1 Expression on Blood Monocytes Study PFS (months) mOS (months) Historical data* 5.0 – 9.0 14.6 - 18.8 Prophage in ndGBM Single arm, open label Ph 2 17.8 23.8 n=46 Prophage in ndGBM More Elevated PD-L1 on PBMs 11.6

  23. Slide 23: HSP70 Synthetic Peptide Vaccine for Anti-viral Immunotherapy

    Slide 23: HSP70 Synthetic Peptide Vaccine for Anti-viral Immunotherapy

    HSP70 Synthetic Peptide Vaccine for Anti-viral Immunotherapy Recombinant human Synthetic peptide heat shock protein 70 immunogens from HSV2 antigenome heat shock protein- peptide complexes (32 different 35mers) Successful Phase 2 Study (n=70) IL-2 >75% w T cell anti-peptide response CD28 B7 MHC I an

  24. Slide 24: HSP70 Synthetic Peptide Vaccine for Anti-viral Immunotherapy

    Slide 24: HSP70 Synthetic Peptide Vaccine for Anti-viral Immunotherapy

    HSP70 Synthetic Peptide Vaccine for Anti-viral Immunotherapy Recombinant human Synthetic peptide heat shock protein 70 immunogens from HSV2 antigenome heat shock protein- peptide complexes (32 different 35mers) Successful Phase 2 Study (n=70) >75% w T cell anti-peptide response >50% w CD8+ T cell re

  25. Slide 25: HSP70 Synthetic Peptide Vaccine for Anti-cancer Immunotherapy

    Slide 25: HSP70 Synthetic Peptide Vaccine for Anti-cancer Immunotherapy

    HSP70 Synthetic Peptide Vaccine for Anti-cancer Immunotherapy Recombinant human Synthetic peptide neo- heat shock protein 70 epitope immunogens from NGS heat shock protein- peptide complexes CD8 & CD4 T cell responses against patient’s neo-epitopes expected Positive POC in animal models QS-21 Stimul

  26. Slide 26: AutoSynVax (ASV) Off-the-shelf and Individualized Cancer Vaccines

    Slide 26: AutoSynVax (ASV) Off-the-shelf and Individualized Cancer Vaccines

    AutoSynVax™ (ASV™) Off-the-shelf and Individualized Cancer Vaccines 1 2 Sequence Identify and Patient’s Tumor Tumor Functionally Genome Characterize Mutations 3 Identify Candidate Immunogenic Neoantigens 5 4 Produce Incorporate Neoantigen- into containing Individualized Vaccine Vaccine Blueprint Pre

  27. Slide 27: Phosphopeptide Neo-epitopes (Phosphotopes)

    Slide 27: Phosphopeptide Neo-epitopes (Phosphotopes)

    Phosphopeptide Neo-epitopes (Phosphotopes) Breakthrough Path to Tumor & Patient-specific but NOT Individualized Vaccines Phosphotopes Phosphotopes - Fragments of mis-phosphorylated characterized from multiple tumor types proteins uniquely presented by MHCs on cancer cells - True neo-epitopes suitabl

  28. Slide 28: Innovative Neo-epitope-targeted HSP-based Vaccines

    Slide 28: Innovative Neo-epitope-targeted HSP-based Vaccines

    Innovative Neo-epitope-targeted HSP-based Vaccines Combine with CPM AutoSynVax™ Patient’s Tumor and IM mAbs as appropriate Next Generation Sequencing of Tumor Genome Prophage™ Purify HSPs Complexed with Peptide Neoantigens Identify Mutations and Candidate Neoantigens PhosphoSynVax™ Personalized Vacc

  29. Slide 29: Challenges and Opportunities in I-O

    Slide 29: Challenges and Opportunities in I-O

    Challenges and Opportunities in I-O Variable Tumor Immunogenicity: Inadequately Addressed Currently Unrecognizable as Non-self recognition too weak Seen as non-self non-self? Phosphotopes Vaccines +/- CPMs CPM COMBOS + CPMs Median per tumor Agenus, unpublished data Agenus Creating Individually Optim

Source: Internet Archive copy of agenusbio.com

More decks from Agenus Inc.

All 34 Agenus decks